The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 601–700 of 1,006
Ghanakota, P., Bos, P. H., Konze, K. D., Staker, J., Marques, G. F. F., Marshall, K., Leswing, K., Abel, R., & Bhat, S. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00120 · Cited by 56
Accelerating therapeutic protein design with computational approaches toward the clinical stage
Chen, Z., Wang, X., Chen, X., Huang, J., Wang, C., Wang, J., & Wang, Z. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.04.027 · Cited by 55
“These principles have linked the physicochemical and biopharmacological properties of small molecules to their developability, including solubility, hydrophobicity, penetration, stability, and crystallization properties [59].”
BackgroundXu, H., Tang, H., Feng, H., & Li, Y. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.11.044 · Cited by 49
Hay, T. L., Jones, R. D. O., Beaumont, K. C., & Kemp, M. I. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027888 · Cited by 49
“All the compounds were “rule of five”-compliant (Lipinski, 2000; Leeson and Springthorpe, 2007); therefore, adequate oral absorption was expected.”
BackgroundAdvances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds
Fernandes, G., Chin, C. M., & dos Santos, J. L. (2017) · Pharmaceuticals · doi:10.3390/ph10020051 · Cited by 51
“Among these st ps, the determination of the physicochemi al properties of potentially active compounds plays an important role in the init al stages [70,71].”
BackgroundTanini, D., Scarpelli, S., Ermini, E., & Capperucci, A. (2019) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201900168 · Cited by 49
Improving Compound Quality through in vitro and in silico Physicochemical Profiling
Waterbeemd, H. V. D. (2009) · Chemistry & Biodiversity · doi:10.1002/cbdv.200900056 · Cited by 51
Kiani, Y. S., & Jabeen, I. (2019) · ACS Omega · doi:10.1021/acsomega.9b02344 · Cited by 56
Sanapalli, B. K. R., Ashames, A., Sigalapalli, D. K., SHAIK, A. B., Bhandare, R. R., & Yele, V. (2022) · Antibiotics · doi:10.3390/antibiotics11121680 · Cited by 48
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 – 2010)
Zhan, P., & Liu, X. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.568481 · Cited by 48
“, potency/size, ligand-lipophilicity efficiency, LLE) was introduced and used as an important metric both to guide the drug discovery program teams during the lead optimization phase and to better assess the developability potential of a drug candidate [205,206].”
MethodThe Chembl Database: A Taster for Medicinal Chemists
Papadatos, G., & Overington, J. P. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.8 · Cited by 48
Braggio, S., Montanari, D., Rossi, T., & Ratti, E. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.490553 · Cited by 48
“, ligand efficiency [8]; lipophilicity ligand efficiency [9]; ligand efficiency logP [10]; 3/75 rule [11]).”
BackgroundCrawford, T. D., Ndubaku, C. O., Chen, H., Boggs, J. W., Bravo, B. J., Delatorre, K. J., Giannetti, A. M., Gould, S. E., Harris, S. F., Magnuson, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500155b · Cited by 48
Batch and Flow Synthesis of Pyrrolo[1,2-a]-quinolines via an Allene-Based Reaction Cascade
Baumann, M., & Baxendale, I. R. (2015) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5b01982 · Cited by 48
Lomonosova, E. E., Daw, J., Garimallaprabhakaran, A. K., Agyemang, N. B., Ashani, Y., Murelli, R. P., & Tavis, J. E. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.06.014 · Cited by 48
“Lipophilicity can reflect a key event of molecular desolvation in transfer from aqueous phases to cell membranes and to proteins binding sites (Leeson and Springthorpe, 2007).”
Su, Y., Elmes, M. W., Tong, S., Hu, K., Awwa, M., Teng, G. Y. H., Jing, Y., Freitag, M., Gan, Q., Clement, T., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.050 · Cited by 49
“In addition, the lipophilicity of the designed compounds was also taken into account since the partition coefficient (LogP) provides important information about bioavailability, as well as necessary drug formulation and delivery [21, 22].”
BackgroundTadić, J. D., Lađarević, J., Vitnik, Ž., Vitnik, V., Stanojković, T., Matić, I. Z., & Mijin, D. (2020) · Dyes and Pigments · doi:10.1016/j.dyepig.2020.109123 · Cited by 48
Hopkins, B. T., Bame, E., Bajrami, B., Black, C., Bohnert, T., Boiselle, C., Burdette, D., Burns, J. C., Delva, L., Donaldson, D., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00926 · Cited by 44
Acetylation turns leucine into a drug by membrane transporter switching
Churchill, G. C., Strupp, M. L., Factor, C., Brémovà-Ertl, T., Factor, M., Patterson, M. C., Platt, F. M., & Galione, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95255-5 · Cited by 47
Li, Y., Liu, T., & Sun, J. (2023) · Molecules · doi:10.3390/molecules28020733 · Cited by 50
Fragment-to-Lead Medicinal Chemistry Publications in 2022
Woodhead, A., Erlanson, D. A., de Esch, I. J. P., Holvey, R. S., Jahnke, W., & Pathuri, P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02070 · Cited by 52
Antinociceptive properties of caffeic acid derivatives in mice
Buzzi, F. D. C., Franzoi, C. L., Antonini, G., Fracasso, M., Filho, V. C., Yunes, R. A., & Niero, R. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.06.029 · Cited by 47
Hepatitis C Replication Inhibitors That Target the Viral NS4B Protein
Miller, J. F., Chong, P. Y., Shotwell, J. B., Catalano, J. G., Tai, V. W. ‐., Fang, J., Banka, A. L., Roberts, C. D., Youngman, M., Zhang, H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400125h · Cited by 50
MacLellan, P., & Nelson, A. S. (2013) · Chemical Communications · doi:10.1039/c2cc38184b · Cited by 47
Sulfonimidamide in medizinischer Chemie und Agrochemie
Chinthakindi, P. K., Naicker, T., Thota, N., Govender, T., Kruger, H. G., & Arvidsson, P. I. (2016) · Angewandte Chemie · doi:10.1002/ange.201610456 · Cited by 51
Butler, L. D., Guzzie‐Peck, P., Hartke, J., Bogdanffy, M. S., Will, Y., Diaz, D., Mortimer‐Cassen, E., Derzi, M., Greene, N., & DeGeorge, J. J. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.05.009 · Cited by 51
Munawar, S., Windley, M. J., Tse, E. G., Todd, M. H., Hill, A. P., Vandenberg, J. I., & Jabeen, I. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01035 · Cited by 47
Dhameliya, T. M., Patel, K. I., Tiwari, R., Vagolu, S. K., Panda, D., Sriram, D., & Chakraborti, A. K. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104538 · Cited by 50
Barreca, M. L., Manfroni, G., Leyssen, P., Winquist, J., Kaushik‐Basu, N., Paeshuyse, J., Krishnan, R., Iraci, N., Sabatini, S., Tabarrini, O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301643a · Cited by 47
Procopiou, P. A., Barrett, J. W., Barton, N. P., Begg, M., Clapham, D., Copley, R. C. B., Ford, A. J., Graves, R. H., Hall, D. A., Hancock, A. P., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301572h · Cited by 47
Reddy, D. S., Hosamani, K. M., Devarajegowda, H. C., & Kurjogi, M. M. (2015) · RSC Advances · doi:10.1039/c5ra09508e · Cited by 46
Is there a link between selectivity and binding thermodynamics profiles?
Tarcsay, Á., & Keserű, G. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.014 · Cited by 50
Baumann, M., Baxendale, I. R., Kuratli, C., Ley, S. V., Martin, R. E., & Schneider, J. (2011) · ACS Combinatorial Science · doi:10.1021/co2000357 · Cited by 46
Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
Estrada, A. A., & Sweeney, Z. K. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00261 · Cited by 51
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure
Lanier, M. C., Pickens, J., Bigi-Botterill, S. V., Bradshaw‐Pierce, E. L., Chambers, A., Cheruvallath, Z. S., Cole, D. C., Dougan, D. R., Ermolieff, J., Gibson, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00481 · Cited by 46
Pinto, P., Machado, C. M., Moreira, J., Almeida, J. D. P., Silva, P. M. A., Henriques, A. C., Soares, J. X., Salvador, J. A. R., Afonso, C., Pinto, M. M. M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111752 · Cited by 47
Nugraha, A. S., Triatmoko, B., Wangchuk, P., & Keller, P. A. (2020) · Biomolecules · doi:10.3390/biom10020181 · Cited by 46
“Generally, medicinally active secondary metabolites have a water solubility problem likely related to the lipophilic moieties in their structures [62].”
BackgroundFragment-to-Lead Medicinal Chemistry Publications in 2021
Walsh, L. M., Erlanson, D. A., de Esch, I. J. P., Jahnke, W., Woodhead, A., & Wren, E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01827 · Cited by 47
Leach, A. G., & Kidley, N. J. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci2000506 · Cited by 49
Shahzan, S., Girija, A. S. S., & Jayaseelan, V. P. (2019) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2019.100899 · Cited by 56
Gesmundo, N. J., Dykstra, K. D., Douthwaite, J. L., Kao, Y.-T., Zhao, R., Mahjour, B. A., Ferguson, R., Dreher, S. D., Sauvagnat, B., Saurí, J., et al. (2023) · Nature Synthesis · doi:10.1038/s44160-023-00351-1 · Cited by 45
“The robotic liquid handlers typically used in low-volume reagent doing rely on involatile, uniform reagent stock solutions with low viscosity.”
MethodNing, Y., Chen, H., Ning, Y., Zhang, J., & Bi, X. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318072 · Cited by 45
Hollinshead, S. P., Tidwell, M. W., Palmer, J. R., Guidetti, R., Sanderson, A. J., Johnson, M. P., Chambers, M. G., Oskins, J. L., Stratford, R. E., & Astles, P. C. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400305d · Cited by 49
Oslob, J. D., Johnson, R. J. K., Cai, H., Feng, S., Hu, L. J., Kosaka, Y., Lai, J., Sivaraja, M., Tep, S., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300335r · Cited by 45
McCoull, W., Addie, M. S., Birch, A. M., Birtles, S., Buckett, L. K., Butlin, R. J., Bowker, S. S., Boyd, S., Chapman, S., Davies, R. D. M., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.117 · Cited by 45
T-type calcium channels inhibitors: a patent review
Giordanetto, F., Knerr, L., & Wållberg, A. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.536532 · Cited by 45
“2) [103], thus, suggesting that many of the herein described compounds are unlikely to successfully progress to clinical development.”
BackgroundBertrand, S. M., Ancellin, N., Beaufils, B., Bingham, R. P., Borthwick, J. A., Boullay, A.-B., Boursier, E. V., Carter, P. S., Chung, C., Churcher, I., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00313 · Cited by 47
Chelli, S. M., Alagumuthu, M., Sridhar, P., Sivakumar, A., Belliraj, S. K., & Reddy, S. R. (2017) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2017.10.075 · Cited by 45
Nitroketene N , S -acetals: synergistic building blocks for the synthesis of heterocycles
Saigal, S., Khan, S., Rahman, H., Shafiullah, S., & Khan, M. M. (2019) · RSC Advances · doi:10.1039/c9ra00630c · Cited by 45
Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone
Kung, P., Sinnema, P.-J., Richardson, P., Hickey, M. J., Gajiwala, K. S., Wang, F., Huang, B., McClellan, G. A., Wang, J., Maegley, K. A., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.04.130 · Cited by 47
Delivering on the promise of recombinant silk-inspired proteins for drug delivery
González‐Obeso, C., Hartzell, E. J., Scheel, R. A., & Kaplan, D. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114622 · Cited by 47
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108107 · Cited by 61
Liu, T., Yang, H., Jiang, Y., & Fu, H. (2013) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201300044 · Cited by 44
Díaz, J. L., Christmann, U., Fernández, A., Torrens, A., Port, A., Pascual, R., Álvarez, I., Burgueño, J., Monroy, X., Montero, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501920g · Cited by 44
Hoque, I., Chatterjee, A., Bhattacharya, S., & Biswas, R. (2017) · International Journal of Advanced Research in Biological Sciences (IJARBS) · doi:10.22192/ijarbs.2017.04.02.009 · Cited by 44
“…EXCRETION, TOXICITY) AND DRUG SAFETY PREDICTION: Lipinski's rule is related to ADMET (absorption, distribution, metabolism, excretion and toxicity) which states that, in general, an orally active drug has no more than one violation of the following components (22,23,24,25,26,27,28,29) : 1.”
BackgroundThe safety of non-biological treatments in Ulcerative Colitis
Troncone, E., & Monteleone, G. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1340936 · Cited by 46
“administered orally, thus improving patient satisfaction and avoiding infusion reactions [143,144].”
BackgroundChannar, P. A., Saeed, A., Larik, F. A., Rashid, S., Iqbal, Q., Rozi, M., Younis, S., & Mahar, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.139 · Cited by 47
“Ligand efficiency (LE) and lipophilic efficiency (LipE or LLE) profiles of inhibitors were used to identify the hits with higher activities using Equation 1 and 2 [80,81].”
MethodOrgan‐on‐a‐Chip Systems for Women's Health Applications
Nawroth, J. C., Rogal, J., Weiß, M., Brucker, S. Y., & Loskill, P. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700550 · Cited by 47
Konkankit, C. C., Vaughn, B. A., Huang, Z., Boros, E., & Wilson, J. J. (2020) · Dalton Transactions · doi:10.1039/d0dt01097a · Cited by 44
Recent Experimental Developments in Studying Passive Membrane Transport of Drug Molecules
Gh., M. S. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00009 · Cited by 50
Ikeda, S., Sugiyama, H., Tokuhara, H., Murakami, M., Nakamura, M., Oguro, Y., Aida, J., Morishita, N., Sogabe, S., Dougan, D. R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00432 · Cited by 47
Jones, K. L., Beaumont, D. M., Bernard, S. G., Bit, R. A., Campbell, S. P., Chung, C., Cutler, L., Demont, E. H., Dennis, K., Gordon, L. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00855 · Cited by 44
Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors
Crawford, J. J., Lee, W., Aliagas, I., Mathieu, S., Hoeflich, K. P., Zhou, W., Wang, W., Rougé, L., Murray, L. J., La, H., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00572 · Cited by 44
Strategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 48
Musonda, C. C., Whitlock, G. A., Witty, M. J., Brun, R., & Kaiser, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.098 · Cited by 44
Molecular Property Filters Describing Pharmacokinetics and Drug Binding
García‐Sosa, A. T., Maran, U., & Hetényi, C. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799945021 · Cited by 45
“An analysis by Leeson and Springthorpe [45] suggested that clogP is the most important molecular property, as it is changing less over decades in launched oral drugs than other properties.”
BackgroundMethodChloroquine–astemizole hybrids with potent in vitro and in vivo antiplasmodial activity
Musonda, C. C., Whitlock, G. A., Witty, M. J., Brun, R., & Kaiser, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.047 · Cited by 44
Quantifying the hydrogen-bond propensity of drugs and its relationship with Lipinski's rule of five
Haritha, M., Sreerag, M., & Suresh, C. H. (2024) · New Journal of Chemistry · doi:10.1039/d3nj05476d · Cited by 43
Lansdell, M. I., Hepworth, D., Calabrese, A., Brown, A. D., Blagg, J., Burring, D. J., Wilson, P., Fradet, D., Brown, T. B., Quinton, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9017866 · Cited by 43
Egieyeh, S. A., Syce, J. A., Malan, S. F., & Christoffels, A. G. (2016) · Malaria Journal · doi:10.1186/s12936-016-1087-y · Cited by 43
“In other words, it evaluates how well compounds improve potency while maintaining low lipophilicity [81].”
BackgroundResultScott, J. S., deSchoolmeester, J., Kilgour, E., Mayers, R. M., Packer, M. J., Hargreaves, D., Gerhardt, S., Ogg, D., Rees, A., Selmi, N., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301252n · Cited by 44
Drug‐Mediated Regulation of Glycosaminoglycan Biosynthesis
Ghiselli, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21429 · Cited by 46
Structure-Based Design of Highly Selective Inhibitors of the CREB Binding Protein Bromodomain
Denny, R. A., Flick, A. C., Coe, J. W., Langille, J., Basak, A., Liu, S., Stock, I. A., Sahasrabudhe, P. V., Bonin, P. D., Hay, D. A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01839 · Cited by 43
King, T. A., Stewart, H. L., Mortensen, K. T., North, A. J. P., Sore, H. F., & Spring, D. R. (2019) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201900847 · Cited by 44
Soliman, N., McKenzie, L. K., Karges, J., Bertrand, E., Tharaud, M., Jakubaszek, M., Guérineau, V., Goud, B., Hollenstein, M., Gasser, G., et al. (2020) · Chemical Science · doi:10.1039/c9sc05976h · Cited by 46
Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
Krutzek, F., Kopka, K., & Stadlbauer, S. (2022) · Pharmaceuticals · doi:10.3390/ph15060747 · Cited by 45
“However, many developed small molecule drugs possess molecular weights above 500 Da [99,100].”
BackgroundZehnder, L. R., Bennett, M. J., Meng, J. J., Huang, B., Ninkovic, S., Wang, F., Braganza, J., Tatlock, J. H., Jewell, T., Zhou, J. Z., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200128m · Cited by 43
Which three-dimensional characteristics make efficient inhibitors of protein–protein interactions?
Kuenemann, M. A., Bourbon, L. M. L., Labbé, C. M., Villoutreix, B. O., & Sperandio, O. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500487q · Cited by 42
Peng, X., Zhao, J., Ma, G., Wu, Y. J., Hu, S., Ruan, Z., & Feng, P. (2021) · Green Chemistry · doi:10.1039/d1gc02821a · Cited by 42
Exploring the Biologically Relevant Chemical Space for Drug Discovery
Deng, Z.-L., Du, C.-X., Li, X., Hu, B., Kuang, Z., Wang, R., Feng, S., Zhang, H., & De, K. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400432a · Cited by 45
Kinetic efficiency: the missing metric for enhancing compound quality?
Holdgate, G., & Gill, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.006 · Cited by 42
Scott, D. E., Coyne, A. G., Venkitaraman, A. R., Blundell, T. L., Abell, C., & Hyvönen, M. (2014) · ChemMedChem · doi:10.1002/cmdc.201402428 · Cited by 43
Wager, T. T., Kormos, B. L., Brady, J. T., Will, Y., Aleo, M. D., Stedman, D. B., Kuhn, M., & Chandrasekaran, R. Y. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401485p · Cited by 42
Mekheimer, R. A., Abuo‐Rahma, G. E. A., Abd‐Elmonem, M., Yahia, R., Hisham, M., Hayallah, A. M., Mostafa, S. M., Abo-Elsoud, F. A., & Sadek, K. U. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133615 · Cited by 42
Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates
Böcker, A., Bonneau, P. R., Hucke, O., Jakalian, A., & Edwards, P. J. (2010) · ChemMedChem · doi:10.1002/cmdc.201000355 · Cited by 49
Warr, W. A. (2009) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-009-9292-1 · Cited by 42
In silico validation and ADMET analysis for the best lead molecules
Pradeepkiran, J. A., Sainath, S. B., & Shrikanya, K. V. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85681-2.00008-2 · Cited by 41
Musa, A., Ihmaid, S. K., Hughes, D. L., Said, M. A., Abulkhair, H. S., El-Ghorab, A. H., Abdelgawad, M. A., Shalaby, K., Shaker, M. E., Alharbi, K. S., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2167000 · Cited by 41
“It could be used to increase drug potency without increasing Log P (Leeson & Springthorpe, 2007).”
BackgroundSharma, L. K., Leonardi, R., Lin, W., Boyd, V. A., Goktug, A. N., Shelat, A. A., Chen, T., Jackowski, S., & Rock, C. O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501585q · Cited by 41
Plowright, A., Engkvist, O., Gill, A., Knerr, L., & Wang, Q.-D. (2014) · Angewandte Chemie · doi:10.1002/anie.201307034 · Cited by 39
A new paradigm for navigating compound property related drug attrition
Barton, P., & Riley, R. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.010 · Cited by 48
Guardia, A., Gülten, G., Fernandez, R., Gómez, J., Wang, F., Convery, M. A., Blanco, D., Martínez, M., Pérez‐Herrán, E., Alonso, M., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600020 · Cited by 41
Aleo, M. D., Shah, F., He, K., Bonin, P. D., & Rodrigues, A. D. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00048 · Cited by 42
Lorthiois, E., Anderson, K., Vulpetti, A., Rogel, O., Cumin, F., Ostermann, N., Steinbacher, S., Sweeney, A. M., Delgado, O., Liao, S.-M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00425 · Cited by 41
Chen, H., Volgraf, M., Do, S., Kolesnikov, A., Shore, D. G., Verma, V. A., Villemure, E., Wang, L., Chen, Y., Hu, B., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00117 · Cited by 41
Bagal, S. K., Andrews, M. D., Bechle, B. M., Bian, J., Bilsland, J., Blakemore, D. C., Braganza, J., Bungay, P. J., Corbett, M. S., Cronin, C. N., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00633 · Cited by 43
McCoull, W., Boyd, S., Brown, M. R., Coen, M., Collingwood, O., Davies, N. L., Doherty, A., Fairley, G., Goldberg, K., Hardaker, E. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00920 · Cited by 41
Kingwell, K. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3058 · Cited by 41
Tosatti, P., Horn, J., Campbell, A. J., House, D., Nelson, A. S., & Marsden, S. P. (2010) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201000721 · Cited by 41
Hoveyda, H. R., Fraser, G. L., Roy, M., Dutheuil, G., Batt, F., Bousmaqui, M. E., Korac, J., Lenoir, F., Lapin, A., Noël, S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5017413 · Cited by 42
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.